Logo image of BCLI

BRAINSTORM CELL THERAPEUTICS (BCLI) Stock Price, Quote, News and Overview

NASDAQ:BCLI - Nasdaq - US10501E3009 - Common Stock - Currency: USD

1.73  -0.07 (-3.89%)

BCLI Quote, Performance and Key Statistics

BRAINSTORM CELL THERAPEUTICS

NASDAQ:BCLI (2/21/2025, 8:02:56 PM)

1.73

-0.07 (-3.89%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High11.89
52 Week Low1.05
Market Cap9.86M
Shares5.70M
Float4.45M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-31 2025-03-31/amc
IPO05-28 2003-05-28


BCLI short term performance overview.The bars show the price performance of BCLI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 -40 -60

BCLI long term performance overview.The bars show the price performance of BCLI in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of BCLI is 1.73 USD. In the past month the price decreased by -19.91%. In the past year, price decreased by -66.95%.

BRAINSTORM CELL THERAPEUTICS / BCLI Daily stock chart

BCLI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About BCLI

Company Profile

BCLI logo image Brainstorm Cell Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 29 full-time employees. The company went IPO on 2003-05-28. BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The firm is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. The company has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.

Company Info

BRAINSTORM CELL THERAPEUTICS

1325 Avenue Of Americas, 28th Floor

New York City NEW YORK 10019 US

CEO: Chaim Lebovits

Employees: 29

Company Website: https://brainstorm-cell.com/

Investor Relations: http://ir.brainstorm-cell.com

Phone: 12014880460

BRAINSTORM CELL THERAPEUTICS / BCLI FAQ

What is the stock price of BRAINSTORM CELL THERAPEUTICS today?

The current stock price of BCLI is 1.73 USD. The price decreased by -3.89% in the last trading session.


What is the ticker symbol for BRAINSTORM CELL THERAPEUTICS stock?

The exchange symbol of BRAINSTORM CELL THERAPEUTICS is BCLI and it is listed on the Nasdaq exchange.


On which exchange is BCLI stock listed?

BCLI stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BRAINSTORM CELL THERAPEUTICS stock?

8 analysts have analysed BCLI and the average price target is 14.11 USD. This implies a price increase of 715.8% is expected in the next year compared to the current price of 1.73. Check the BRAINSTORM CELL THERAPEUTICS stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BRAINSTORM CELL THERAPEUTICS worth?

BRAINSTORM CELL THERAPEUTICS (BCLI) has a market capitalization of 9.86M USD. This makes BCLI a Nano Cap stock.


How many employees does BRAINSTORM CELL THERAPEUTICS have?

BRAINSTORM CELL THERAPEUTICS (BCLI) currently has 29 employees.


What are the support and resistance levels for BRAINSTORM CELL THERAPEUTICS (BCLI) stock?

BRAINSTORM CELL THERAPEUTICS (BCLI) has a support level at 1.71 and a resistance level at 1.81. Check the full technical report for a detailed analysis of BCLI support and resistance levels.


Should I buy BRAINSTORM CELL THERAPEUTICS (BCLI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BRAINSTORM CELL THERAPEUTICS (BCLI) stock pay dividends?

BCLI does not pay a dividend.


When does BRAINSTORM CELL THERAPEUTICS (BCLI) report earnings?

BRAINSTORM CELL THERAPEUTICS (BCLI) will report earnings on 2025-03-31, after the market close.


What is the Price/Earnings (PE) ratio of BRAINSTORM CELL THERAPEUTICS (BCLI)?

BRAINSTORM CELL THERAPEUTICS (BCLI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.46).


What is the Short Interest ratio of BRAINSTORM CELL THERAPEUTICS (BCLI) stock?

The outstanding short interest for BRAINSTORM CELL THERAPEUTICS (BCLI) is 2.05% of its float. Check the ownership tab for more information on the BCLI short interest.


BCLI Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to BCLI. When comparing the yearly performance of all stocks, BCLI is a bad performer in the overall market: 80.82% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BCLI Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to BCLI. Both the profitability and financial health of BCLI have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BCLI Financial Highlights

Over the last trailing twelve months BCLI reported a non-GAAP Earnings per Share(EPS) of -3.46. The EPS decreased by -685.58% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -702.62%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-264.29%
Sales Q2Q%N/A
EPS 1Y (TTM)-685.58%
Revenue 1Y (TTM)N/A

BCLI Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to BCLI. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners7.35%
Ins Owners17.71%
Short Float %2.05%
Short Ratio1.11
Analysts
Analysts85
Price Target14.11 (715.61%)
EPS Next Y75.67%
Revenue Next YearN/A